General Information of Drug (ID: DMQ5K8R)

Drug Name
N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine Drug Info
Synonyms CHEMBL374320; N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine; SCHEMBL4381145
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10389852
TTD Drug ID
DMQ5K8R

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IB-MECA DM9G5XD Psoriasis vulgaris EA90 Phase 3 [2]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [3]
NITD609 DMQHBSX Malaria 1F40-1F45 Phase 2 [4]
CF102 DMP56WJ Hepatocellular carcinoma 2C12.02 Phase 2 [5]
SCH-442416 DMQ2K1V N. A. N. A. Phase 1 [6]
AST-004 DM5WMG7 Stroke 8B20 Phase 1 [7]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [8]
BAY 60-6583 DMTEJV1 Myocardial ischemia BA6Z Preclinical [9]
CF602 DM0ULO2 Inflammation 1A00-CA43.1 Preclinical [5]
CF502 DMQSJ20 Inflammation 1A00-CA43.1 Preclinical [5]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [10]
Istradefylline DM20VSK Parkinson disease 8A00.0 Approved [11]
Regadenoson DM76VHG Radionuclide imaging N.A. Approved [12]
Tozadenant DMATC14 Parkinson disease 8A00.0 Phase 3 [13]
Binodenoson DMVHF8G Hypertension BA00-BA04 Phase 3 [14]
Apadenoson DMD8QTC Coronary artery disease BA80 Phase 3 [15]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [3]
Dexefaroxan DMTY4KN Parkinson disease 8A00.0 Phase 2 [16]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [17]
BIIB014 DMH7RJ1 Parkinson disease 8A00.0 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [10]
Rolofylline DMSZPR3 Heart failure BD10-BD13 Phase 3 [19]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [3]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [17]
SELODENOSON DMQM3IX Cardiac arrhythmias BC9Z Phase 2 [20]
Apaxifylline DMQMV9F Cognitive impairment 6D71 Phase 2 [21]
SLV320 DM867BJ Heart failure BD10-BD13 Phase 2 [22]
DTI-0009 DMV84OK Atrial fibrillation BC81.3 Phase 2 [20]
Capadenoson DMYWO62 Atrial fibrillation BC81.3 Phase 2 [23]
BAY 1067197 DM4JGNH Heart failure BD10-BD13 Phase 2 [24]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A1 receptor (ADORA1) TTK25J1 AA1R_HUMAN Inhibitor [1]
Adenosine A2a receptor (ADORA2A) TTM2AOE AA2AR_HUMAN Inhibitor [1]
Adenosine A3 receptor (ADORA3) TTJFY5U AA3R_HUMAN Inhibitor [1]

References

1 N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30.
2 A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
3 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
4 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
5 2011 Pipeline of Can-Fite BioPharm.
6 Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
7 Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
8 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
9 Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
10 Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
13 Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
14 Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
16 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
17 Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
18 Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
19 Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
20 Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
22 Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
23 A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
24 Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.